News

How HeSANDA is Revolutionising Australian Medical Research

Imagine a world where medical research doesn’t have to start from scratch. Imagine a treasure trove of valuable data readily available to answer new questions and fuel groundbreaking discoveries. This is the reality HeSANDA, the Health Studies Australian National Data Asset, is creating for Australian researchers.

HeSANDA: More Than Just a Database

HeSANDA is not your typical research database. It’s a national program that goes beyond simply storing data. It facilitates the discovery, access, and sharing of health and medical research data from clinical trials, cohort studies, and other valuable sources. It aims to support more efficient and effective research to help improve health outcomes.

This translates to several key benefits:

  • Reduced research waste: No more repeating studies already conducted. Researchers can leverage existing data to answer new questions and refine hypotheses.
  • Enhanced collaboration: HeSANDA fosters collaboration between researchers across Australia, leading to richer, more impactful projects.
  • Faster research breakthroughs: By readily accessing existing data, researchers can accelerate the pace of discovery and deliver results faster.

How Does HeSANDA Work?

HeSANDA is a powerful search engine for health research data. Researchers can use the platform by:

  • Search for datasets: HeSANDA allows searching of detailed descriptions for various clinical trials and other research projects.
  • Request data access: Once a relevant dataset is identified, researchers can request access to the de-identified individual participant data from the data custodian.
  • Ensure data security: HeSANDA prioritises data security. All users must agree to a data sharing agreement, and participant data is always de-identified to protect privacy.

Who Benefits from HeSANDA?

HeSANDA’s impact extends far beyond individual researchers. Here’s how it benefits various stakeholders in the medical research landscape:

Australia: HeSANDA maximises the return on investment in research by enabling data reuse for new discoveries and collaborations.

Research participants: Participants contribute to more research without additional time commitment, maximizing the value of their participation.

Research organisations: HeSANDA boosts research reputation, grant applications, and collaboration opportunities. It also enhances research rigor by facilitating reproducibility.

Health services: HeSANDA supports improved research practices and leverages existing data for better service development.

Data providers (researchers who created the data): HeSANDA increases recognition for their work, extends the life of their research, and facilitates new collaborations.

Data users (researchers seeking data): HeSANDA sparks new research questions, streamlines collaboration, reduces research duplication, and accelerates discovery.

Funders: HeSANDA maximises the value of research grants by promoting data reuse.

Who is involved with HeSANDA?

There are 9 HeSANDA nodes that represent 72 health research organisations across Australia.

Melbourne Academic Centre for Health (MACH) Clinical Trials Consortium Node
Administered by: The University of Melbourne

Mental Health Node
Administered by: Deakin University

Monash and Partners Node
Administered by: Monash University

National Cancer Cooperative Trials Groups Node
Administered by: Australasian Leukaemia and Lymphoma Group (ALLG)

Northern Australia Node
Administered by: Menzies School of Health Research

Queensland Node
Administered by: Health Translation Queensland in collaboration with CSIRO’s Australian e-Health Research Centre and Queensland Cyber Infrastructure Foundation (QCIF).

South Australia Node
Administered by: South Australian Health and Medical Research Institute (SAHMRI)

Sydney Health Partners Node
Administered by: NHMRC Clinical Trials Centre at The University of Sydney

Western Australia Node
Administered by: Curtin University

TOGA: Contributing to the HeSANDA Ecosystem

At TOGA, we are involved in HeSANDA through contributing valuable datasets from the NITRO and DREAM trials to further enrich the national data pool.


The Future of Medical Research is Collaborative

HeSANDA is a game-changer for Australian medical research. By fostering data sharing and collaboration, it pavessthe way for faster discoveries and ultimately, improved health outcomes for all.

Whether you’re a researcher seeking valuable data or a data provider looking to maximise the impact of your work, HeSANDA is a valuable resource. Explore the platform, discover its potential, and contribute to the future of Australian medical research.

Share this

Facebook
Twitter
LinkedIn
Learn what a KRAS G12C mutation means, how targeted therapies work, and how Australian clinical trials are testing new lung cancer treatments.
The PHARAOH-A trial will evaluate savolitinib plus osimertinib in MET-positive amplified or overexpressed EGFR-mutated lung cancer after progression on prior TKI and chemotherapy.
New evidence is changing the way surgeons approach early-stage lung cancer, with lung-sparing surgery becoming an option for carefully selected patients.
Everything you need to know about the Australia-wide trial using liquid biopsy to guide treatment after targeted therapy progression in advanced lung cancer
The DEFIANT trial will evaluate datopotamab deruxtecan (Dato-DXd) in EGFR exon 20 insertion NSCLC after targeted therapy and chemotherapy.
Discover the major advances from TOGA ASM 2026, including lung cancer screening, precision medicine, immunotherapy, survivorship and multidisciplinary care shaping the future of thoracic oncology.
Professor Robert Stirling OAM devoted his career to improving the lives of people with lung cancer through clinical excellence, research, education and compassionate leadership.
Their work is often invisible, but its impact isn't. Specialist Lung Cancer Nurses are quietly becoming the backbone of modern lung cancer care.
Teletrials, also known as digi trials, are when a clinician at a primary site uses telehealth (videoconference or telephone calls) to enrol, consent, treat and/or
A simple guide to what happens after a lung CT scan in the Australian National Lung Cancer Screening Program
Updates from our Inspirational Research Grant 2025 recipients on pioneering lung microbiome research and its impact on immunotherapy efficacy.
Clinicians, nurses, consumers and health service leaders came together at TOGA’s Lung Cancer Optimal Care Pathway workshop to examine why Australia continues to struggle to
Understanding the language helps patients, families and clinicians stay informed, confident and part of the conversation.
TOGA is pleased to announce the latest appoints for our Scientific Committee.
Discover how a vibrant Lunar New Year Banquet, organised by Dr. Angeline Low and Ms. Maria Chan, raised over $50,000 for vital lung cancer research.
The MRFF is holding $1B+ in unspent funds. Learn why TOGA is calling for the release of this research funding to accelerate lung cancer breakthroughs
Discover TOGA’s FY25 highlights, including the new Strategic Plan, clinical trial milestones and record membership growth across Australia and New Zealand.
The Preventative and Quality Care Working Group represents TOGA’s commitment to improving the outcomes of thoracic cancers.
TOGA’s Working Groups are evolving to better reflect where thoracic cancer research is heading: From prevention and early detection through to advanced disease and living
Learn how to turn your endorsed research concept into a clinical trial; from sponsor selection to budgeting, data, safety and protocol design.
Learn how to design an investigator-initiated clinical trial, from refining your research idea to securing TOGA endorsement and funding.
Learn why EGFR-positive lung cancer disproportionately affects Asian populations and non-smokers. Discover modern targeted therapies and symptoms to watch for.
Discover how 2025 transformed lung cancer care in Australia. Explore the impact of national screening, modern diagnostics, and new PBS treatment approvals.
Let's take a moment to celebrate the incredible guests, ground breaking discussions, and dedicated listeners that made 2025 our most successful year yet.
If you are interested in joining TOGA on a Committee, please submit your nominations by 30 January 2026
The final Scientific Meeting of 2025 was held in November. Five concepts were presented, spanning both Recurrent and Metastatic NSCLC populations and four Mesothelioma concepts.
Bispecific antibodies target two pathways at once, reshaping lung cancer treatment through dual checkpoint blockade and targeted precision.
Research advances only improve outcomes when they are accessible to patients. TOGA drives change in lung cancer care by advocating through stakeholder submissions, including PBS.......
We are excited about awarding new grants but first, we check in on progress made by our 2024 recipients....
Learn how TOGA’s ASPiRATION study led to Medicare-funded genomic testing for lung cancer and national best practice guidelines in Australia.
Optimise cancer care for older Adults with practical tips and tools to implement person-centred geriatric oncology.
DYNAMALK is a significant clinical trial investigating the potential of comprehensive genomic profiling to revolutionise the treatment of ALK+ Non-Small Cell Lung Cancer (NSCLC)
Liquid biopsy is revolutionising lung cancer care by using a blood test to examine the tumour without the need for a lung biopsy.
OCEANiC will determine if patients with resected stage II to IIIA EGFR mutant NSCLC require intensification of osimertinib monotherapy with chemotherapy.
Latest results from the SHERLOCK clinical trial show promising first-line outcomes for patients with KRAS G12C-mutated lung cancer, combining sotorasib with chemotherapy and bevacizumab.
A re-cap of the Scientific Committee meeting in August 2025 and the year to date.